Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Cash from Financing Activities (2019 - 2025)

Historic Cash from Financing Activities for IDEAYA Biosciences (IDYA) over the last 7 years, with Q3 2025 value amounting to $301000.0.

  • IDEAYA Biosciences' Cash from Financing Activities fell 9989.49% to $301000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $30.4 million, marking a year-over-year decrease of 9627.29%. This contributed to the annual value of $677.6 million for FY2024, which is 8679.88% up from last year.
  • Per IDEAYA Biosciences' latest filing, its Cash from Financing Activities stood at $301000.0 for Q3 2025, which was down 9989.49% from $1.2 million recorded in Q2 2025.
  • IDEAYA Biosciences' 5-year Cash from Financing Activities high stood at $349.1 million for Q1 2024, and its period low was $301000.0 during Q3 2025.
  • In the last 5 years, IDEAYA Biosciences' Cash from Financing Activities had a median value of $26.1 million in 2025 and averaged $69.0 million.
  • As far as peak fluctuations go, IDEAYA Biosciences' Cash from Financing Activities soared by 12344117.65% in 2021, and later tumbled by 9989.49% in 2025.
  • Quarter analysis of 5 years shows IDEAYA Biosciences' Cash from Financing Activities stood at $688000.0 in 2021, then tumbled by 52.91% to $324000.0 in 2022, then surged by 43385.8% to $140.9 million in 2023, then crashed by 98.05% to $2.8 million in 2024, then crashed by 89.07% to $301000.0 in 2025.
  • Its last three reported values are $301000.0 in Q3 2025, $1.2 million for Q2 2025, and $26.1 million during Q1 2025.